SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors react to the company's expansion into pharmaceutical manufacturing and the launch of new regulated laboratory products, fueling speculation about potential U.S. government contracts and domestic supply chain partnerships. The community remains focused on the company's improved balance sheet and its strategic pivot toward advanced materials, with active discussions on the long-term potential for a major industrial turnaround.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heavy volatility as traders debate the sustainability of its parabolic rally following its S&P 500 inclusion and massive AI-driven infrastructure demand. The community is sharply divided between bulls citing mission-critical optical networking bottlenecks and bears warning of a potential liquidity trap or bubble valuation.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 ETF is experiencing intense volatility and aggressive price swings as the market reacts to speculative headlines regarding geopolitical tensions and potential protocols for shipping routes. The community is deeply polarized, with many retail traders accusing large institutions of orchestrating 'fake' rallies to trap bears and manipulate options liquidity before a long holiday weekend.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Guy ($RAGE) is trending as the community doubles down on "OG meme" culture, driven by the restoration of classic comic-making tools on the Solana blockchain. Investors are emphasizing high-conviction "bag holding" and long-term building as they contrast their project's historical cultural relevance against what they describe as short-lived, "forced" meme tickers.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is rallying as the space sector gains momentum ahead of the Artemis II mission launch, with investors closely watching for impact on the broader orbital infrastructure market. The community remains highly active, debating the potential for a short squeeze while contrasting current mission optimism against lingering concerns over share offerings.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is experiencing heightened volatility and intense social media debate, driven by uncertainty surrounding geopolitical developments in the Middle East and the market's reaction to recent presidential commentary. The community remains deeply divided, with significant arguments playing out between bulls anticipating a classic dip-buy and bears pointing toward escalating oil prices and macroeconomic concerns as catalysts for a broader sell-off.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

KELYB is seeing intense community activity driven by its extremely low float, which investors believe creates the potential for rapid volatility and short squeezes. Traders are closely monitoring upcoming investor calls and the influence of major institutional positions, with many debating whether the current price action represents a temporary pullback or a setup for further gains.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is surging as geopolitical tensions intensify following a recent presidential address that signaled a prolonged military conflict with Iran, dashing market hopes for a de-escalation. The community is actively debating the potential for long-term oil supply disruptions, with many traders monitoring the Strait of Hormuz for toll-related developments while gauging the sustainability of the price move amidst warnings of a wider economic slowdown.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention ahead of its upcoming earnings report, with the community actively debating the company's shift toward a diversified consumer goods strategy and the potential for a significant rally should federal rescheduling news materialize. Despite frustrations over historical share price volatility and management's dilution strategy, bullish sentiment remains tied to improving medical cannabis fundamentals and hopes for a major short squeeze.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors digest news of its controlling shareholder, Centurium Capital, acquiring the Blue Bottle Coffee brand, sparking speculation about a potential strategic pivot toward a multi-brand global platform. The community remains focused on the company's valuation, institutional accumulation by major firms like First Beijing Investment, and the ongoing debate regarding a long-anticipated relisting on a major U.S. exchange.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendatio...

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...

Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Hennion & Walsh Asset Management Inc. cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 36.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,163 shares of the biopha...

Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent...

United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis.</li><li>The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis.</li><li>The company licensed global rights to six pre-clinical siRNA programs in February for up to $4.4 billion to expand its pipeline.</li></ul>Shares of Madrigal Pharmaceuticals Inc. (MDGL) closed 12% higher on Thursday on buyout speculation by pharma giant Eli Lilly and Company (LLY).The rumors originated after Madrigal featured on the Betaville <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.betaville.co.uk/betaville-intelligence/jrxmz7f0s1g9fqz992bo8ioi2lq6x3suvsc7">blog</a>, which highlights potential corporate transactions. The blog highlighted that the news is market gossip and added that it might be “total codswallop.”<h2 class="st-heading-2">Madrigal’s MASH Focus</h2>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious, progressive liver disease marked by fat accumulation, inflammation, and cell damage.The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis. The company is also evaluating the drug for the treatment of compensated MASH cirrhosis.<h2 class="st-heading-2">Madrigal’s Financials</h2>For full-year 2025, the company reported Rezdiffra net sales of $958.4 million. There were more than 36,250 patients on Rezdiffra as of the end of 2025, the company said.The company also licensed global rights to six pre-clinical siRNA programs from Suzhou Ribo Life Science Co. Ltd. &nbsp;and its subsidiary Ribocure Pharmaceuticals AB in February for up to $4.4 billion to expand its pipeline. The company is looking to undertake non-clinical studies for some of the candidates in 2026.In January, the company announced an exclusive global license agreement with Pfizer for Ervogastat in yet another attempt to expand its MASH pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MDGL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user opined that Lilly will be a great company to care for Madrigal while adding that the buyout must value the company between $800-$1000 per share.<stembedurl>https://www.stocktwits.com/sarkar20/message/648675460</stembedurl>Another proposed the idea of the company merging with Viking Therapeutics instead. Viking is developing a drug candidate called VK2809 for MASH as well.<stembedurl>https://www.stocktwits.com/vu_jade/message/648680850</stembedurl><a href="https://stocktwits.com/symbol/MDGL">MDGL stock</a> has gained 55% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-as-retail-traders-pile-into-obesity-pipeline-bets/cZ3sB3KRIlO">VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation

The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.

Equity

The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.


Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% Higher - Should You Buy?

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 11.7% - Should You Buy...

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

MDGL
Madrigal Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MDGL News

MDGLMadrigal Pharmaceuticals Inc